---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011083"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T09:10:44.761882+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biofrontera reports record FY 2024 revenue $37.3M, up 9.5% YoY; Q4 net loss $1.4M

## Summary
- Record total revenues $37.3M for 2024, +9.5% from $34.1M in 2023; Q4 revenues $12.6M, +18.5% YoY.
- Q4 2024 net loss $1.4M ($0.19/share) vs net income $3.5M ($1.65/share) in Q4 2023 due to prior-year legal settlement gain.
- Cash and equivalents $5.9M at Dec 31, 2024 vs $1.3M at Dec 31, 2023; Ameluz transfer price reduced from 50% to 25% through 2025.
- Placed 100 RhodoLED XL lamps since June 2024 launch; FDA approved up to 3 tubes of Ameluz per treatment.
- Phase 3 Study for Ameluz-PDT in superficial BCC achieved statistically significant results; initiated Phase 1 PK study for AK.

## SEC filing metadata
- accession: 0001493152-25-011083
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315225011083/0001493152-25-011083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315225011083/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011083
- JSON: https://secwatch.observer/filing/0001493152-25-011083.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.